SecSonar.com

Janux Therapeutics, Inc. (JANX)

Janux Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Janux Therapeutics, Inc. (JANX) is a Biotechnology company based in US with a market capitalization of $894.3M. Revenue declined 5.5% year-over-year and free cash flow was negative at -$83.3M. This page tracks JANX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 91 employees · IPO Jun 11, 2021

Valuation

Valuation & price

$13.89 · as of May 17, 2026 · -60.0% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

0.93

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$34.74$23.91$13.08Jul 25Dec 25Jul 26Jul 7, 25$23.96Jul 9, 25$25.49Jul 11, 25$25.15Jul 15, 25$25.76Jul 17, 25$27.75Jul 21, 25$26.08Jul 23, 25$26.46Jul 25, 25$25.96Jul 29, 25$24.17Jul 31, 25$24.02Aug 4, 25$23.91Aug 6, 25$24.18Aug 11, 25$22.67Aug 13, 25$24.96Aug 15, 25$25.11Aug 19, 25$24.70Aug 21, 25$24.00Aug 25, 25$23.01Aug 27, 25$23.35Aug 29, 25$22.72Sep 3, 25$23.04Sep 5, 25$23.98Sep 9, 25$23.78Sep 11, 25$25.12Sep 16, 25$23.41Sep 18, 25$24.40Sep 22, 25$23.51Sep 24, 25$22.84Sep 26, 25$23.23Sep 30, 25$24.44Oct 2, 25$23.31Oct 6, 25$22.76Oct 8, 25$24.20Oct 10, 25$26.51Oct 14, 25$25.73Oct 16, 25$27.20Oct 21, 25$26.83Oct 23, 25$24.46Oct 27, 25$27.35Oct 29, 25$27.81Oct 31, 25$28.71Nov 4, 25$27.01Nov 6, 25$28.66Nov 10, 25$27.59Nov 12, 25$28.52Nov 14, 25$29.28Nov 18, 25$29.02Nov 20, 25$28.59Nov 25, 25$34.74Nov 28, 25$34.09Dec 2, 25$15.86Dec 4, 25$16.40Dec 8, 25$16.58Dec 10, 25$15.58Dec 12, 25$15.30Dec 16, 25$14.65Dec 18, 25$14.04Dec 22, 25$14.09Dec 24, 25$14.31Dec 29, 25$14.07Jan 2, 26$13.65Jan 6, 26$13.44Jan 8, 26$13.91Jan 12, 26$14.03Jan 14, 26$14.12Jan 16, 26$13.76Jan 21, 26$13.27Jan 23, 26$14.81Jan 27, 26$14.73Jan 29, 26$13.83Feb 2, 26$13.99Feb 4, 26$13.33Feb 9, 26$13.27Feb 11, 26$13.11Feb 13, 26$13.14Feb 18, 26$13.21Feb 20, 26$13.08Feb 24, 26$13.65Feb 26, 26$13.80Mar 2, 26$13.42Mar 4, 26$14.35Mar 6, 26$13.84Mar 10, 26$14.07Mar 12, 26$13.95Mar 17, 26$14.05Mar 19, 26$14.16Mar 23, 26$13.90Mar 25, 26$13.80Mar 27, 26$13.18Mar 31, 26$13.90Apr 2, 26$14.84Apr 7, 26$14.93Apr 9, 26$14.53Apr 13, 26$14.90Apr 15, 26$15.04Apr 17, 26$15.82Apr 22, 26$15.39Apr 24, 26$15.01Apr 28, 26$14.50Apr 30, 26$14.37May 4, 26$14.42May 6, 26$14.62May 8, 26$14.18May 12, 26$14.41May 14, 26$14.39May 18, 26$14.03May 20, 26$14.40May 22, 26$14.52May 28, 26$14.74Jun 1, 26$14.41Jun 3, 26$13.59Jun 5, 26$13.36Jun 9, 26$13.62Jun 11, 26$13.66Jun 15, 26$13.74Jun 17, 26$14.15Jun 22, 26$14.34Jun 24, 26$14.64Jun 26, 26$14.94Jul 2, 26$15.54
$12.1852-week range$34.74
Loading valuation history…

Fundamentals

Key fundamentals

$894.3M

Market cap

-5.5%

Revenue growth (YoY)

79.7%

Gross margin

-$83.3M

Free cash flow (USD)

-$944.4M

Net debt

Net cash position

15.3%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2019 → 2025

FY 2019$0.00FY 2020$0.00FY 2021$3.6MFY 2022$8.6MFY 2023$8.1MFY 2024$10.6MFY 2025$10.0M
$0$10M

Free cash flow by year

2019 → 2025

FY 2019$-3.8MFY 2020$-4.4MFY 2021$-18.5MFY 2022$-49.4MFY 2023$-52.4MFY 2024$-44.2MFY 2025$-83.3M
-$3.8M-$83.3M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 202290.2%FY 202375.8%FY 202480.5%FY 202579.7%
100.0%79.7%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

2

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventCMO DepartureJun 23, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 12, 2026Filing
  • Insider sellInsider Sell $57KDoyle Janeen Noel · Chief Corp. & Bus. Dev. Ofcr · $56.9KJun 4, 2026Filing
  • Insider sellInsider Sell $29KDobek Maria · Vice President, Accounting · $28.9KMay 13, 2026Filing
  • 8-K eventEarnings ReleaseMay 7, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • 8-K eventDirector ReclassificationApr 28, 2026Filing

Questions

Frequently asked questions

What is Janux Therapeutics, Inc.'s market cap?

Janux Therapeutics, Inc. (JANX) has a market capitalization of $894.3M.

What is JANX's P/E ratio?

A meaningful P/E ratio is not available for JANX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is JANX's price-to-book (P/B) ratio?

JANX trades at 0.93 times book value per share.

Are insiders buying JANX stock?

SEC Form 4 filings show no open-market insider buys at Janux Therapeutics, Inc. in the last 90 days (2 sells).

Same arena

Related companies in Biotechnology

KURA

Kura Oncology, Inc.

$900.2M

XNCR

Xencor, Inc.

$885.3M

SPRY

ARS Pharmaceuticals, Inc.

$908.6M

ABUS

Arbutus Biopharma Corporation

$922.5M

PHAR

Pharming Group N.V.

$942.8M

TBPH

Theravance Biopharma, Inc.

$835.7M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.